CSU secures award from U.S. government for development of SolaVAX™ vaccine manufacturing process for SARS-CoV-2
A team of infectious disease researchers at Colorado State University has entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to further develop a novel virus inactivation process, successfully used for MERS, which has the potential to inactivate the SARS-CoV-2 virus.